Global Animal Blood Products Market Size By Type (Bovine, Sheep), By Application (Scientific Research, Industrial Production), By Region, And Segment Forecasts, 2023 to 2032

The Global Animal Blood Products Market was valued at USD 2.1 billion in 2023 and is projected to surpass USD 3.7 billion by 2031, growing at a CAGR of 7.2% during the forecast period (2023–2031). The growth is fueled by rising demand for high-quality animal-derived bioproducts in pharmaceuticals, diagnostics, and animal feed. As the biopharmaceutical and veterinary healthcare industries expand globally, the application of animal blood derivatives such as plasma proteins, immunoglobulins, fibrinogen, and albumin is seeing notable uptake. The market is also benefitting from growing research activities, especially in cell culture media and vaccine development.

Drivers:

1. Rising Demand in Biopharmaceutical and Diagnostic Sectors:

Animal blood products serve as critical components in diagnostic kits, cell culture, and biopharmaceutical manufacturing, especially in vaccine and antibody production. The increasing use of these products in research labs and commercial diagnostics is propelling market growth.

2. Expansion of Veterinary Healthcare and Livestock Sector:

The growth in animal husbandry, pet care, and veterinary diagnostics is creating robust demand for blood-derived products that support health monitoring, immunization, and therapeutic interventions.

3. Increasing Applications in Animal Nutrition:

Blood meal and plasma proteins are gaining popularity as high-value protein supplements in animal feed, especially for swine and poultry, due to their digestibility and immune-supportive roles.

Restraints:

1. Ethical and Regulatory Constraints:

The collection, processing, and use of animal blood products are subject to strict animal welfare and biosafety regulations, which can hinder scalability and cross-border trade.

2. Quality and Contamination Risks:

Maintaining product quality and preventing contamination are major challenges in blood product processing. Batch variability and safety concerns limit product usage, particularly in high-sensitivity applications.

Opportunity:

1. Growth in Cell Culture Media and Vaccine Development:

The booming biotechnology sector offers new growth avenues, as animal serum and plasma are integral to the development of vaccines and monoclonal antibodies. Ongoing R&D initiatives are expected to elevate demand for purified and specialized blood derivatives.

2. Emerging Markets and Livestock Industrialization:

Regions like Asia-Pacific and Latin America are seeing rapid expansion in their livestock and veterinary sectors, supported by rising disposable incomes, modernization of farming practices, and government support for animal health programs.

Market by Product Type Insights:

The Plasma Powder segment accounted for the largest revenue share in 2023. Its broad utility in feed, pharmaceuticals, and laboratory applications makes it a cornerstone of the market. This segment is expected to retain dominance due to its protein-rich profile and functional properties in both feed formulation and medical research.

The Immunoglobulin segment is projected to grow at the highest CAGR during the forecast period, driven by increasing interest in passive immunity for neonatal animals and therapeutic applications in humans.

Market by End-use Insights:

Pharmaceutical & Research Laboratories emerged as the largest end-use segment in 2023. With increasing investment in biopharmaceutical R&D and vaccine production, demand for animal-derived proteins and serums has surged significantly.

Animal Feed & Pet Food Manufacturers represent a fast-growing segment, propelled by the demand for performance-enhancing and immunity-boosting feed additives in commercial livestock and aquaculture.

Market by Regional Insights:

North America led the global market in 2023, driven by a strong biopharma sector, robust veterinary services, and advanced regulatory frameworks. The U.S. remains a major hub for plasma fractionation and research-based applications.

Asia-Pacific is anticipated to witness the fastest growth rate during the forecast period, due to increased livestock production, expanding animal healthcare access, and rising adoption of western veterinary practices in countries such as China, India, and Vietnam.

Competitive Scenario:

Leading companies in the Global Animal Blood Products Market include LAMPIRE Biological Laboratories, Thermo Fisher Scientific, Bovogen Biologicals Pty Ltd, Kraeber & Co GmbH, Proliant Biologicals, Quad Five, Auckland BioSciences, and Rocky Mountain Biologicals. These firms focus on expanding production capacity, improving product standardization, and entering strategic partnerships to meet rising global demand.

Scope of Work – Global Animal Blood Products Market

Key Market Developments:

2023: Thermo Fisher Scientific expanded its animal serum production facilities to support rising global bioprocessing demand.

2024: Bovogen Biologicals launched a high-purity immunoglobulin product line targeted at research and vaccine development.

2025: Proliant Biologicals entered a distribution agreement with a major Asian biotech firm to scale its reach in developing markets.

FAQs:

1) What is the current market size of the Global Animal Blood Products Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Animal Blood Products Market?

The primary driver is rising demand in biopharmaceuticals, diagnostics, and animal feed sectors.

3) Which is the largest region during the forecast period in the Global Animal Blood Products Market?

North America leads the market due to its mature healthcare and biotech infrastructure.

4) Which segment accounted for the largest market share in Global Animal Blood Products Market?

The Plasma Powder segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Animal Blood Products Market?

Key players include Thermo Fisher Scientific, LAMPIRE Biological Laboratories, Bovogen Biologicals, Proliant Biologicals, and Quad Five.